J Bone Metab.  2013 Nov;20(2):95-98. 10.11005/jbm.2013.20.2.95.

The Necessity of Bone Densitometry for Patients Taking Selective Serotonin Reuptake Inhibitors

• An KY
• Shin WJ
• Lee KJ

• KMID: 2286300
• DOI: http://doi.org/10.11005/jbm.2013.20.2.95

Abstract

BACKGROUND
To analyze the necessity of bone densitometry for patients long-term taking selective serotonin reuptake inhibitors (SSRI) over a long period of time, which is one of the risk factors of osteoporosis.
METHODS
We selected patients from 5 veterans hospitals who took SSRI for more than 2 months while taking bone densitometry on a regular basis.
RESULTS
Of the 85 patients from a total of 5 veterans hospitals taking SSRI for more than two months, only 34 patients were under diagnosis and treatment measures of osteoporosis through checking each person's bone mineral density.
CONCLUSIONS
It is necessary for patients taking SSRI to check bone density on a regular basis.

Keyword

Osteoporosis; Prevalence; Serotonin uptake inhibitors

MeSH Terms

Bone Density
Densitometry*
Diagnosis
Hospitals, Veterans
Humans
Osteoporosis
Prevalence
Risk Factors
Serotonin Uptake Inhibitors*
Serotonin Uptake Inhibitors

Figure

• 

  Fig. 1 Number of taking selective serotonin reuptake inhibitors patients for more than 2 monthsin the 5 veterans hospital for more than 2 months. DM, diabetes mellitus.

Reference

1. Kang MI, Koh JM, Kim T, et al. Physician's guide for diagnosis & treatment of osteoporosis. Seoul: Korean Society for Bone and Mineral Research;2008.

2. Cummings SR, Black DM, Nevitt MC, et al. The Study of Osteoporotic Fractures Research Group. Appendicular bone density and age predict hip fracture in women. JAMA. 1990; 263:665–668.

3. Yirmiya R, Bab I. Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry. 2009; 66:423–432.

4. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007; 167:188–194.

5. Pacher P, Ungvari Z, Kecskemeti V, et al. Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity. Br J Pharmacol. 1999; 127:740–746.

6. Ungvari Z, Pacher P, Kecskeméti V, et al. Fluoxetine dilates isolated small cerebral arteries of rats and attenuates constrictions to serotonin, norepinephrine, and a voltage-dependent Ca (2+) channel opener. Stroke. 1999; 30:1949–1954.

7. Cherin P, Colvez A, Deville de Periere G, et al. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol. 1997; 50:313–320.

8. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:85–102.

9. Ministry of Health & Welfare. Korea Centers for Disease Control and Prevention. Korea health statistics 2009: Korea national health and nutrition examination survey (KNHANESIV-3). Seoul: Ministry of Health & Welfare;2010.

10. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007; 167:1246–1251.

11. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135:825–837.

12. Ohayon MM, Hong SC. Prevalence of major depressive disorder in the general population of South Korea. J Psychiatr Res. 2006; 40:30–36.

13. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003; 326:1014.

14. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ. 1995; 310:1433–1438.

15. Barbui C, Hotopf M, Freemantle N, et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev. 2000; 4:CD002791.